当前位置：
X-MOL 学术
›
Eur. J. Immunol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity
European Journal of Immunology ( IF 4.5 ) Pub Date : 2021-08-04 , DOI: 10.1002/eji.202149277 Andreas E Kremer 1, 2 , Anita N Kremer 3 , Carsten Willam 4 , Simon Völkl 3 , Johan Verhagen 3 , Susanne Achenbach 5 , Edith D van der Meijden 3 , Vanessa Lang 3 , Michael Aigner 3 , Clara Maier 6 , Matthias Tenbusch 6 , Klaus Korn 6 , Gloria Lutzny-Geier 3 , Silvia Spoerl 3 , Richard Strauß 2 , Marcel Vetter 2 , Klaus Überla 6 , Markus F Neurath 2 , Andreas Mackensen 3 , Mario Schiffer 4 , Holger Hackstein 5
European Journal of Immunology ( IF 4.5 ) Pub Date : 2021-08-04 , DOI: 10.1002/eji.202149277 Andreas E Kremer 1, 2 , Anita N Kremer 3 , Carsten Willam 4 , Simon Völkl 3 , Johan Verhagen 3 , Susanne Achenbach 5 , Edith D van der Meijden 3 , Vanessa Lang 3 , Michael Aigner 3 , Clara Maier 6 , Matthias Tenbusch 6 , Klaus Korn 6 , Gloria Lutzny-Geier 3 , Silvia Spoerl 3 , Richard Strauß 2 , Marcel Vetter 2 , Klaus Überla 6 , Markus F Neurath 2 , Andreas Mackensen 3 , Mario Schiffer 4 , Holger Hackstein 5
Affiliation
|
Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID-19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, neutralizing antibodies are a key requisite in the fight against viral infections. Patients depleted of antibody-producing B cells, such as those treated with rituximab (anti-CD20) for hematological malignancies, lack a fundamental part of their adaptive immunity. Treatment with convalescent plasma appears to be of general benefit in this particularly vulnerable cohort. We analyzed clinical course and inflammation markers of three B-cell-depleted patients suffering from COVID-19 who were treated with convalescent plasma. In addition, we measured serum antibody levels as well as peripheral blood CD38/HLA-DR-positive T-cells ex vivo and CD137-positive T-cells after in vitro stimulation with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-derived peptides in these patients. We observed that therapy with convalescent plasma was effective in all three patients and analysis of CD137-positive T-cells after stimulation with SARS-CoV-2 peptides showed an increase in peptide-specific T-cells after application of convalescent plasma.
中文翻译：
用恢复期血浆在 B 细胞耗竭患者中成功治疗 COVID-19 感染可促进细胞免疫
恢复期血浆治疗已被证明在 2019 年冠状病毒病 (COVID-19) 感染中是安全的，尽管在免疫功能正常的患者中报告的疗效各不相同。然而，中和抗体是对抗病毒感染的关键必要条件。缺乏产生抗体的 B 细胞的患者，例如用利妥昔单抗（抗 CD20）治疗血液恶性肿瘤的患者，缺乏其适应性免疫的基本部分。在这个特别脆弱的人群中，恢复期血浆治疗似乎具有普遍的益处。我们分析了三名接受恢复期血浆治疗的 B 细胞耗尽的 COVID-19 患者的临床病程和炎症标志物。此外，我们在体外用严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 衍生肽刺激后测量了血清抗体水平以及离体外周血 CD38/HLA-DR 阳性 T 细胞和 CD137 阳性 T 细胞在这些患者中。我们观察到恢复期血浆治疗对所有三名患者都是有效的，并且在用 SARS-CoV-2 肽刺激后对 CD137 阳性 T 细胞的分析显示，在应用恢复期血浆后，肽特异性 T 细胞增加。
更新日期：2021-10-06
中文翻译：
用恢复期血浆在 B 细胞耗竭患者中成功治疗 COVID-19 感染可促进细胞免疫
恢复期血浆治疗已被证明在 2019 年冠状病毒病 (COVID-19) 感染中是安全的，尽管在免疫功能正常的患者中报告的疗效各不相同。然而，中和抗体是对抗病毒感染的关键必要条件。缺乏产生抗体的 B 细胞的患者，例如用利妥昔单抗（抗 CD20）治疗血液恶性肿瘤的患者，缺乏其适应性免疫的基本部分。在这个特别脆弱的人群中，恢复期血浆治疗似乎具有普遍的益处。我们分析了三名接受恢复期血浆治疗的 B 细胞耗尽的 COVID-19 患者的临床病程和炎症标志物。此外，我们在体外用严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 衍生肽刺激后测量了血清抗体水平以及离体外周血 CD38/HLA-DR 阳性 T 细胞和 CD137 阳性 T 细胞在这些患者中。我们观察到恢复期血浆治疗对所有三名患者都是有效的，并且在用 SARS-CoV-2 肽刺激后对 CD137 阳性 T 细胞的分析显示，在应用恢复期血浆后，肽特异性 T 细胞增加。
京公网安备 11010802027423号